# US 2001/0027208 A1 · Radicicol derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027208 A1
- Document ID: US20010027208A1
- Status: Published application
- Kind: A1
- Application number: 09/791,602
- Filed: 2001-02-26
- Published: 2001-10-04
- Earliest claimed: 1996-10-25
- Assignees: Kyowa Hakko Kogyo Co., Ltd.
- Inventors: Yoji Ino; Nobuyoshi Amishiro; Mayumi Miyata; Chikara Murakata; Harumi Ogawa; Tadakazu Akiyama; Shiro Akinaga; Shiro Soga; Yukimasa Shiotsu
- Web page: https://patentgrep.com/patent/US20010027208A1

## CPC

- C07D 493/04: Ortho-condensed systems
- C07D 313/00: Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Radicicol derivatives represented by the following formula (I) having tyrosine kinase inhibition activity or pharmacologically acceptable salts thereof: 1 wherein R1 and R2 are the same or different, and each represents hydrogen, alkanoyl, alkenoyl, tert-butyldiphenylsilyl or tert-butyldimethylsilyl; R 3 represents Y—R5 {wherein Y represents substituted or unsubstituted alkylene; and R5 represents CONR7 (wherein R6 represents hydrogen, hydroxyl, substituted or unsubstituted lower alkyl, substituted or unsubstituted higher alkyl, and the like; R7 represents hydroxyl, substituted lower alkyl, and the like), CO2R12 (wherein R12 represents substituted lower alkyl, substituted or unsubstituted higher alkyl, and the like), and the like} and the like; X represents halogen or is combined together with R4 to represent a single bond ; and R 4 is combined together with X to represent a single bond, or represents hydrogen, alkanoyl, and the like.

## Claims

### Claim 1

A radicicol derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof: 104
wherein R1 and R2 are the same or different, and each represents hydrogen, alkanoyl, alkenoyl, tert-butyldiphenylsilyl or tert-butyldimethylsilyl;
R3 represents:
Y—R5 {wherein Y represents substituted or unsubstituted alkylene; and R5 represents CONR6R7 (wherein R6 represents hydrogen, hydroxyl, substituted or unsubstituted lower alkyl, substituted or unsubstituted higher alkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, or NR8R9 (wherein R8 and R9 are the same or different, and each represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted higher alkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, carbonyl bound to a substituted or unsubstituted heterocyclic ring, or substituted or unsubstituted arylcarbamoyl), or is combined together with R7 and adjoining N to represent a substituted or unsubstituted heterocyclic group; and R17 is combined together with R6 and adjoining N to represent a substituted or unsubstituted heterocyclic group, or represents hydroxyl, substituted lower alkyl, substituted or unsubstituted higher alkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, or NR10R11 (wherein R10 and R11 have the sane meaning as R8 and R9 defined above, respectively)), CO2R12 (wherein R12 represents substituted lower alkyl, substituted or unsubstituted higher alkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), substituted or unsubstituted aryl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyridonyl, substituted or unsubstituted pyrrolidonyl, substituted or unsubstituted uracilyl, substituted or substituted piperidyl, substituted or unsubstituted piperidino, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted morpholino, substituted or unsubstituted morpholinyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted thiomorpholino, or substituted or unsubstituted dioxolanyl},
COR13 (wherein R13 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted higher alkyl, substituted or unsubstituted aryl, substituted or unsubstituted lower alkoxy, or NR14R15 (wherein R14 and R15 are the same or different, and each represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted higher alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted pyridyl, or R14 and R15 are combined together with adjoining N to represent a substituted or unsubstituted heterocyclic group)), or
substituted or unsubstituted aryl;
X represents halogen, or is combined together with R4 to represent a single bond; and
R4 is combined together with X to represent a single bond, or represents hydrogen, alkanoyl, alkenoyl, or —SO—Z {wherein Z represents formula (A): 105
wherein R1A and R2A have the same meaning as R1 and R2 defined above, respectively; XA represents halogen; and W represents O or N—O—R3A (wherein R3A has the same meaning as R3 defined above)}.

### Claim 2 (depends on 1)

The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein X is halogen.

### Claim 3 (depends on 1)

The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein X is combined together with R4 to represent a single bond.

### Claim 4 (depends on 3)

The compound according to claim 3 or a pharmacologically acceptable salt thereof, wherein R1 and R2 each is hydrogen.

### Claim 5 (depends on 4)

The compound according to claim 4 or a pharmacologically acceptable salt thereof, wherein R3 is Y—R5.

### Claim 6 (depends on 5)

The compound according to claim 5 or a pharmacologically acceptable salt thereof, wherein R5 is substituted or unsubstituted aryl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyridonyl, substituted or unsubstituted pyrrolidonyl, substituted or unsubstituted uracilyl, substituted or unsubstituted piperidyl, substituted or unsubstituted piperidino, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted morpholino, substituted or unsubstituted morpholinyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted thiomorpholino, or substituted or unsubstituted dioxolanyl.

### Claim 7 (depends on 5)

The compound according to claim 5 or a pharmacologically acceptable salt thereof, wherein R5 is pyrrolidonyl.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A therapeutic agent of diseases caused by tyrosine kinase, which comprises at least one of the compounds according to any one of claims 1 to 6 or a pharmacologically acceptable salt thereof.
